Sarepta Therapeutics Stock Plummets 42.12% in Six Days as Trading Volume Ranks 93rd Amid Second Patient Death

On June 16, 2025, Sarepta Therapeutics (SRPT) experienced a significant decline, with its stock price dropping by 42.12% over the past six days, marking a total decrease of 51.31%. The trading volume for the day was 8.68 billion, ranking 93rd in the market.

Sarepta Therapeutics faced a severe setback as a second patient died following treatment with its gene therapy, Elevidys, for Duchenne muscular dystrophy. The patient succumbed to acute liver failure, as announced by the company on Sunday. This tragic event follows the death of a 16-year-old patient in March, who also died from acute liver failure after receiving the same treatment.

During an investor call on Monday, Sarepta confirmed the details of the second fatality, which occurred within a span of three months. This incident has raised significant concerns about the safety and efficacy of Elevidys, leading to a substantial drop in investor confidence and a sharp decline in the company's stock price.

The company's stock plummeted on Monday, reflecting the market's reaction to the news. The second fatality has cast a shadow over Sarepta's gene therapy program, prompting further scrutiny and potential regulatory implications. The company will likely need to address these issues to regain investor trust and stabilize its stock performance.